A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy

Trial Profile

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Neublastin (Primary)
  • Indications Radiculopathy
  • Focus Therapeutic Use
  • Acronyms SPRINT
  • Sponsors Biogen
  • Most Recent Events

    • 26 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Mar 2015 Planned End Date changed from 1 Feb 2016 to 1 Mar 2015, according to ClinicalTrials.gov record.
    • 08 Mar 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Mar 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top